The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 capsules or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will take place over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will be asked to take the medication orally, in capsule form, and will be regularly assessed by healthcare professionals. The study aims to provide valuable information on whether AVP-786 can be a beneficial treatment option for managing agitation in patients with Alzheimer’s disease. The results will help determine if this medication can improve the quality of life for those affected by this condition.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The medications being tested contain active substances called trospium chloride and xanomeline tartrate. They come in the form of capsules that are taken by mouth. The study will involve patients who have previously participated in related research studies of these medications.

During the study, researchers will monitor various aspects of participants’ health, including any side effects, changes in body weight, blood pressure, heart rate, and mental function. They will also check for any unusual movements, restlessness, and other health-related factors to ensure the medications’ safety over extended use.

Participants in the study will receive either the medication or a placebo and will be monitored over the course of a year. The study will also use a special imaging technique called Florbetaben-PET to measure changes in the brain. This technique involves a solution for injection called Neuraceq, which helps visualize certain brain changes associated with Alzheimer’s Disease. The trial will assess various health markers and cognitive functions to determine the effectiveness of the treatment.

The goal of this research is to better understand how Thiethylperazine might aid in diagnosing and treating early stages of Alzheimer’s Disease. By participating in this study, researchers hope to gather valuable information that could lead to improved treatment options for individuals affected by this condition. The study is expected to continue until the end of 2027, with recruitment starting in late 2025.

The purpose of this study is to assess how Donanemab affects the progression of early symptomatic Alzheimer’s Disease compared to a placebo. Participants will receive either the treatment or a placebo through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants over a period to observe any changes in their condition.

Throughout the study, participants will undergo various assessments, including brain scans using Florbetapir and Flortaucipir, to evaluate the treatment’s impact on Alzheimer’s Disease. These scans help researchers see how the disease progresses and how the treatment might alter this progression. The study aims to provide valuable insights into the safety and effectiveness of Donanemab in managing early Alzheimer’s symptoms.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

The study follows a double-blind design, which means that neither the participants nor the researchers know who is receiving the active medication and who is receiving the placebo. This method is used to prevent bias in the results. During the course of the study, participants will take an oral capsule for a period of time to monitor how the medications affect their symptoms and general well-being.

The purpose of the study is to find out if Trontinemab can slow down the worsening of symptoms in people with early Alzheimer’s Disease when compared to placebo. The study will measure this by looking at changes in thinking abilities, memory, and the ability to perform everyday tasks over a period of 72 weeks. Doctors will use various tests and rating scales to measure these changes, including tests that assess memory, thinking skills, and daily functioning. The study will also look at the safety of Trontinemab by monitoring any unwanted effects that may occur during treatment.

During the study, participants will receive either Trontinemab or placebo through an infusion into a vein. The study will last several years and will involve regular visits to the study site for medical examinations, blood tests, brain scans, and assessments of thinking and memory. Some participants will have additional brain scans using the imaging substances mentioned earlier to help doctors understand how the disease is affecting the brain and whether the treatment is having an effect on certain proteins that build up in the brains of people with Alzheimer’s Disease. Throughout the study, doctors will carefully monitor participants for any side effects and will perform various medical tests to ensure safety.

The purpose of the study is to see if trontinemab can slow down the worsening of symptoms in people with early Alzheimer’s Disease over a period of 72 weeks. During the study, people will receive either trontinemab or placebo through an infusion into a vein. The imaging substances will be given as injections to take special brain scans that show protein deposits linked to Alzheimer’s Disease. These scans help doctors understand what is happening in the brain.

Throughout the study, doctors will check how well people can think, remember things, and carry out everyday tasks using various tests and questionnaires. They will also monitor safety by checking for side effects, doing physical examinations, taking blood samples, and performing brain scans to look for any changes or problems. Some people in the study will have additional tests, including spinal fluid collection to measure certain proteins and extra brain scans to see tau protein, which is another substance that builds up in Alzheimer’s Disease. The study will measure changes in symptoms, brain protein levels, and overall safety of the treatment.

The purpose of this study is to find out if KarXT combined with KarX-EC works better than placebo in reducing agitation in people with Alzheimer’s disease. During the study, the effectiveness of the treatment will be measured using a rating scale that tracks agitation behaviors, such as physical and verbal aggression, and how often these behaviors occur. Doctors will also assess the overall severity of agitation symptoms to see if there is improvement with the treatment.

People taking part in this study will need to have a caregiver who spends enough time with them each week to observe their symptoms and help them follow the study requirements. The caregiver will attend study visits and provide information about the person’s agitation and overall condition. The study will involve taking the study medication or placebo in capsule form by mouth over a period of time, with regular visits to monitor safety and measure changes in agitation symptoms.

The purpose of this study is to evaluate the long-term safety and how well GSK4527226 works in people with early Alzheimer’s Disease. This is an extension study, which means it follows people who have already completed a previous study with the same medication. The study will look at any side effects that occur and will pay special attention to certain brain-related imaging findings that can sometimes happen with this type of treatment. These findings are monitored using brain scans to ensure participant safety throughout the study.

Participants will continue receiving GSK4527226 for up to 104 weeks, which is about two years. During this time, they will attend regular clinic visits where doctors will check their health and monitor for any unwanted effects. The study will also measure changes in memory, thinking abilities, and daily functioning using various assessments and questionnaires. A study partner, such as a family member or close friend who spends regular time with the participant, will need to attend some visits to provide information about how the participant is managing daily activities. All participants in this study will receive the active medication, as this is not a comparison study with placebo.

The study will involve people with mild to moderate Alzheimer’s Disease, who will receive either the study medications or placebo for 24 weeks. The medications are being tested to see if they can help improve cognitive function (thinking abilities) and daily functioning in people with Alzheimer’s Disease.

During the study, participants will take the medication daily and attend regular check-ups where their mental abilities and overall condition will be assessed. The study will track any changes in participants’ ability to think, perform daily activities, and their overall health status. Healthcare providers will monitor participants’ safety throughout the study period.

The study will compare these medications to placebo to see if they can help reduce agitation symptoms in people with Alzheimer’s Disease. During the study, participants will be randomly assigned to receive either the study medications or placebo. Neither the participants nor their doctors will know which treatment they are receiving.

The main way of measuring if the treatment works will be through a special rating scale that measures agitation behaviors. Throughout the study, participants will need to have a caregiver who spends at least 10 hours per week with them to help monitor their condition and assist with taking the medication correctly.

To observe these changes, a specialized imaging technique called PET, or positron emission tomography, will be used. During the process, a substance known as [18F]DED will be administered through an intravenous injection, which means it is delivered directly into a vein. This substance acts as a tracer that allows doctors to see specific activities in the brain through medical scans. This imaging process helps to identify how the brain cells are behaving in different stages of neurodegenerative diseases, which are conditions where the nervous system gradually declines over time.

The study will last for 24 weeks, which is about six months. During this time, people in the study will be checked to see how their thinking abilities, daily activities, and overall condition change. The study will measure changes in memory and thinking using specific tests, and will look at how well people can perform everyday tasks. Doctors will also watch for any unwanted effects that might happen while people are taking the study medicine.

This is a type of study where neither the people taking part nor the doctors know who is getting the real medicine and who is getting placebo until the study is finished. This helps make sure the results are accurate and fair. The study will compare how people do on MK-1167 plus their usual medicine compared to people on placebo plus their usual medicine.

The purpose of this study is to examine how memory-related brain networks are preserved or damaged in different groups of patients with memory disorders from various causes, and to understand the different types of memory strategies that memory experts use. The study will also include healthy people, professional theater actors, and memory athletes who compete in memory competitions. By comparing these different groups, researchers want to learn more about how the brain supports memory and what happens when memory becomes impaired.

Participants will undergo several days of testing and examinations. These will include brain scans using different techniques, memory and thinking tests, questionnaires about daily life and sleep, sleep monitoring, blood tests, and physical measurements. Some participants will receive the imaging substances to allow detailed pictures of their brain to be taken. The study will measure the size of different brain areas, how blood flows through the brain, and the presence of certain proteins that are associated with memory disorders. The information gathered will help researchers understand the brain structures and networks that support memory function in both healthy individuals and those with various memory problems.

The purpose of this study is to see whether donanemab can slow down the worsening of symptoms compared to placebo in people with early symptomatic Alzheimer’s disease. The study will measure changes in memory, thinking abilities, and daily functioning over time to determine if the treatment is effective.

During the study, participants will receive the study medication through an infusion into a vein. The treatment will continue for a period of time while doctors monitor how well participants are doing with their memory and daily activities. Participants will need to have a study partner who knows them well and can provide information about any changes in their condition. The study will use brain scans to check for the presence of certain proteins that are associated with Alzheimer’s disease. These scans help doctors understand the extent of the disease and monitor any changes during the study.

The study will focus on people who have mild to moderate Alzheimer’s Disease, which is a brain condition that affects memory, thinking, and behavior. The medications will be tested to see if they can help improve cognitive function (thinking and memory skills) and overall daily functioning in people with this condition.

During the study, which will last 24 weeks, participants will take the study medications or placebo daily. Healthcare providers will monitor participants’ thinking abilities, daily functioning, and overall condition throughout the study period. They will also check for any side effects or safety concerns that may occur during treatment.

The main purpose of this research is to determine if RO7126209 is safe and well-tolerated when given in multiple increasing doses, and to understand how the medication works in the body. The study will also examine how the drug affects the buildup of amyloid (a protein associated with Alzheimer’s Disease) in the brain using special brain scans called PET scans.

During the study, participants will receive multiple doses of either the study medication or placebo through an infusion into their vein. The study consists of four parts, with different dosing schedules in each part. Throughout the study, participants will undergo various medical examinations, including brain scans, blood tests, and assessments of their thinking abilities. Their safety will be closely monitored through regular check-ups and tests.

During the study, participants will receive either MK-2214 through intravenous infusion (delivery of medication through a vein) or a placebo. Additionally, participants will undergo PET scans (a type of medical imaging) using a substance called Florquinitau F18, which helps doctors see certain changes in the brain related to Alzheimer’s disease.

The study will monitor how the disease progresses over time by measuring changes in brain imaging and performing various tests that assess memory, thinking abilities, and daily living activities. The research team will also track any side effects that participants may experience during the treatment period, which may last up to 100 weeks.

The main purpose is to determine if the treatment can prevent or slow down the buildup of harmful proteins in the brain before memory and thinking problems begin. The study is divided into two stages and will use various methods to measure changes in the brain, including special brain scans and tests of spinal fluid.

Participants will receive either Remternetug as an injection under the skin or a matching placebo for up to 108 weeks. Throughout the study, participants will undergo various tests to monitor their brain health and check for any changes. The study will also track the safety of the treatment by monitoring for side effects and performing regular health checks.

The study will compare VHB937 with placebo over a period of 72 weeks, followed by an extension period. During the study, participants will receive regular infusions of either the study medication or placebo. The study will include people who have early Alzheimer’s Disease, including those with Mild Cognitive Impairment due to Alzheimer’s.

Throughout the study, doctors will monitor changes in participants’ ability to think and perform daily activities. They will use various tests to measure memory and thinking skills, including the Clinical Dementia Rating scale. Participants will undergo regular health checks, including brain MRI scans, to ensure safety. Some participants may continue taking their regular Alzheimer’s medications during the study if they were already using them before joining.

The trial involves people with different conditions, including those with mild cognitive impairment, early Alzheimer’s, and other neurodegenerative disorders. It also includes a group of people without these conditions to compare the results. The study aims to understand how the protein deposits differ between these groups. Participants will undergo brain imaging using the F18-MK6240 to help researchers gather this information.

Throughout the study, participants will have several imaging sessions to track changes in the brain over time. The results will help researchers learn more about how these diseases progress and how they affect the brain. This information could be important for developing new treatments in the future. The study is expected to continue for several years to gather comprehensive data.

The purpose of the study is to gather information on how well [18F]PI-2620 works in identifying tau protein build-up in the brain, which is linked to Alzheimer’s disease in people with Down syndrome. The study will also look at the safety of this imaging agent in both healthy individuals and those with Down syndrome. Participants will receive the injection of [18F]PI-2620 and then undergo a PET scan to see how the agent highlights areas of the brain affected by tau protein.

Throughout the study, participants will be monitored for any side effects for 24 hours after receiving the injection. The study aims to provide valuable insights into the use of [18F]PI-2620 for better understanding and potentially diagnosing Alzheimer’s disease in individuals with Down syndrome over time.

During the study, participants will receive these imaging substances at different times to examine various aspects of brain activity. The substances will help researchers see specific changes in brain cells, particularly focusing on how certain brain cells called microglia become activated and how this affects the connections between brain cells called synapses. Each imaging session involves receiving a small amount of the imaging substance through an intravenous injection.

The imaging will be performed using a special scanning technique called Position Emission Tomography (PET), which creates detailed pictures of the brain. This allows researchers to observe and measure changes in the brain that are characteristic of Alzheimer’s disease. The study will track these changes over time to better understand how the disease progresses and affects different parts of the brain.

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

The purpose of the study is to determine how common and how these amyloid deposits progress in individuals who are part of a larger research project called the ALFA project. Participants will receive injections of the substances Vizamyl and Barnascan, which contain the active substances Flutemetamol (18F) and Fludeoxyglucose (18F), respectively. These substances are given through an injection into a vein, known as intravenous administration. The study will help researchers understand the relationship between amyloid deposits and glucose metabolism in the brain, which could provide insights into the development and progression of Alzheimer’s Disease.

Throughout the study, participants will undergo PET scans to visualize and measure the presence of amyloid deposits and glucose metabolism in their brains. The results will be analyzed to see how these factors vary with age, sex, genetic factors, and family history of Alzheimer’s Disease. This research aims to improve understanding of Alzheimer’s Disease and potentially lead to better ways to diagnose and monitor the condition.

The purpose of the study is to find new ways to diagnose and predict the risk of developing Alzheimer’s Disease in people who do not yet show symptoms. Participants will receive an injection of VIZAMYL and undergo imaging tests to detect amyloid plaques. The study aims to discover new markers and risk factors for Alzheimer’s Disease and to understand how these plaques might lead to cognitive decline over time.

Throughout the study, participants will be monitored to see how the presence of amyloid plaques affects their cognitive health. The study will help researchers learn more about the early stages of Alzheimer’s Disease and potentially lead to better diagnostic tools and treatments in the future.

Participants in the study will receive the treatment through a method called intravenous infusion, which means the plasma is given directly into the bloodstream through a vein. The study will last for about one year, during which the health and well-being of the participants will be closely monitored. The main goal is to observe any side effects and to ensure that the treatment is feasible for patients to undergo.

In addition to monitoring safety, the study will also look at changes in cognitive abilities, which are mental processes like memory and thinking. This will be done using various tests, such as the Mini-Mental State Examination (MMSE) and other cognitive assessments. The results will help determine if the plasma transfusion has any impact on the progression of Alzheimer’s disease symptoms. The study is expected to continue until 2030, providing valuable insights into this potential treatment option.

The study involves the use of Flortaucipir, also known as LY3191748, which is given as an injection into a vein. This substance helps to create detailed images of certain proteins in the brain called tau proteins, which are associated with Alzheimer’s Disease. The imaging procedure will be performed alongside another type of brain scan that looks for a different protein called amyloid.

The research aims to understand how tau and amyloid proteins accumulate in the brain of people who don’t have memory problems, and how genetic factors might influence these changes over time. The study will use brain imaging to track these changes and compare them with other markers related to early Alzheimer’s Disease. Participants will receive a single dose of the imaging substance through an injection into a vein during their scan.

The purpose of the study is to explore how the spread of tau in the brain affects its function, especially in areas related to language. Participants in the study will include individuals with mild to moderate Alzheimer’s disease, those with mild cognitive impairment due to Alzheimer’s, and healthy individuals with and without amyloid, a protein associated with Alzheimer’s. The study will observe how tau affects brain activity and connectivity, which refers to how different parts of the brain communicate with each other.

Throughout the study, participants will receive the imaging agent and undergo various assessments to monitor changes in brain function. The study will help researchers gain a better understanding of Alzheimer’s disease and how it progresses, potentially leading to improved treatments in the future. Some participants may receive a placebo, which is a substance with no active ingredients, to compare the effects of the imaging agent.

During the study, participants will receive the imaging substance [18F]RO6958948 through an injection into a vein. The maximum amount given will be 370 MBq (a measure of radioactivity) as a single dose. The substance allows researchers to see the buildup of tau proteins in the brain, which is important in understanding how Alzheimer’s Disease develops and progresses.

The research will look at how these protein deposits relate to other brain changes that occur in Alzheimer’s Disease. Participants will undergo brain imaging both at a single point in time and over a longer period to track any changes. The study includes people who have previously participated in related research programs at the research center and will continue for several years to monitor changes in the brain over time.

The purpose of the study is to understand how the brain changes in people with Alzheimer’s disease. Researchers will look at how certain brain areas are affected and how these changes relate to the brain’s structure and function. The study will involve taking images of the brain using MRI (Magnetic Resonance Imaging) and PET scans. These images will help researchers see where certain proteins, called tau proteins, build up in the brain. The study will also explore how these protein buildups are connected to changes in brain size and function.

Participants in the study will undergo several brain scans over a period of time. These scans will help researchers gather information about the distribution of tau proteins and how they affect brain networks. The study aims to provide a better understanding of the mechanisms behind Alzheimer’s disease and its impact on the brain. This research could lead to new insights into how the disease progresses and potentially inform future treatments.

Participants in the study will receive either the ITI-1284 tablet or a placebo tablet. The study will last for about 12 weeks, during which participants will take the medication once daily. Throughout the study, participants will be monitored to see how their symptoms change over time. The main goal is to see if there is an improvement in the symptoms of agitation by the end of the study period.

This trial aims to provide valuable information on whether ITI-1284 can be a helpful treatment for managing agitation in people with Alzheimer’s disease. By comparing the effects of ITI-1284 to a placebo, researchers hope to determine the potential benefits and safety of this new treatment option.

The trial involves comparing the effects of ITI-1284 with a placebo, which looks like the real medication but does not contain the active ingredient. Participants in the study will take the medication once daily for a period of six weeks. During this time, researchers will monitor changes in the participants’ symptoms to determine how well the medication works in reducing the symptoms of psychosis.

The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The goal is to provide a clearer understanding of the potential benefits and safety of ITI-1284 for individuals with psychosis related to Alzheimer’s disease.

The study will compare two groups of participants over a period of 96 weeks (about 2 years). One group will receive levetiracetam tablets (either 250 mg or 500 mg), while the other group will receive placebo tablets. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition.

During the study, doctors will track several aspects of participants’ health, including brain activity through electroencephalography (a test that records electrical signals from the brain), brain structure using MRI (a type of detailed brain scan), and various blood tests. They will particularly focus on watching for seizures and checking how well the medication is tolerated by participants.

The purpose of this study is to determine how safe and tolerable NSC001 is for patients, with or without the addition of Trospium Aristo. Participants will be randomly assigned to different groups, with some receiving the actual medication and others receiving a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, ensuring unbiased results. The trial will last for a period of 16 weeks, during which participants will take the medication orally in the form of capsules or film-coated tablets.

Throughout the study, participants will be monitored for any changes in their health, including side effects, vital signs, and overall well-being. Regular assessments will be conducted to track any improvements or changes in their condition. The study aims to gather valuable information that could lead to better treatment options for those living with Alzheimer’s Disease.

During the study, participants will receive either KarXT capsules or placebo capsules to take by mouth. The medication or placebo will be given over a period of several weeks to determine if KarXT helps improve the psychotic symptoms that can occur with Alzheimer’s disease. The study will compare how well KarXT works compared to the placebo in reducing these symptoms.

Before joining the study, participants will need to have brain imaging done using either magnetic resonance imaging (MRI) or computed tomography (CT) to confirm their diagnosis. Throughout the study, doctors will monitor the participants’ symptoms and overall health to evaluate how well the treatment is working and ensure their safety.

Participants in the study will receive either Phenserine or Donepezil over a period of several weeks. Phenserine is taken in capsule form, while Donepezil is available as film-coated tablets. The study will monitor changes in specific markers in the body that are linked to Alzheimer’s disease, as well as the safety and tolerability of the medications. Participants will be observed for any side effects and changes in their health during the study.

The study will also assess how well participants adhere to the treatment schedule and any changes in their cognitive abilities, such as memory and attention, using various tests. The goal is to better understand the potential benefits and risks of these medications in treating early or mild Alzheimer’s disease.